ASTRAZENECA'S

AstraZeneca's Tagrisso Shows Potential as a New Standard of Care in First-Line EGFR-Mutated Lung Cancer at ESMO 2017 Congress

Sunday, September 10, 2017

Commentaires

Articles les plus consultés